Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors.
Resource Type
Editorial & Opinion
Authors
Molica M; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Canichella M; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Colafigli G; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Latagliata R; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Diverio D; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Alimena G; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Foà R; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.; Breccia M; Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.
Source
Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE